SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-049988
Filing Date
2024-04-22
Accepted
2024-04-22 16:10:00
Documents
15
Period of Report
2024-04-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2412347d1_8k.htm   iXBRL 8-K 30990
2 EXHIBIT 99.1 tm2412347d1_exx99-1.htm EX-99.1 9201
6 GRAPHIC tm2412347d1_ex99-1img001.jpg GRAPHIC 3326
  Complete submission text file 0001104659-24-049988.txt   226052

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avbp-20240420.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20240420_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20240420_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2412347d1_8k_htm.xml XML 3815
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent Biopharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 24861289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)